Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Healthy
Interventions: V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Gingival Recession
Interventions: CelTx, Autologous sub-epithelial connective tissue graft; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fever
Interventions: Acetaminophen, placebo; Drug · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 6 Weeks to 9 Months
Enrollment: 374 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Maternal Anxiety, Cesarean Delivery
Interventions: Standard Forearm Restraint, Wrist-Level Gripping Restraint; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alzheimer Disease
Interventions: Azeliragon, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 27
States / cities: Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Sun City, Arizona • Irvine, California + 34 more

Conditions: Obstetric Labour, Premature, Premature Ejaculation
Interventions: GSK557296; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Colorectal Cancer
Interventions: Simethicone, Placebo, sodium sulfate/potassium sulfate/magnesium sulfate solution; Drug
Lead sponsor: MercyOne Des Moines Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Jacksonville, Florida • Clive, Iowa

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more

Conditions: Invasive Candidiasis
Interventions: Caspofungin, Normal Saline; Drug
Lead sponsor: Mycoses Study Group; Network
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Pain, Postoperative, Opioid Use
Interventions: Perioperative Pain Management Education and Counseling; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 14 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium, risperidone; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 10 Years to 20 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Inflammation Corneal, Pain, Postoperative
Interventions: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo; Drug
Lead sponsor: Oculis; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more

Conditions: DYT-1, Dystonia
Interventions: Ampicillin, Sugar pill; Drug
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Participants
Interventions: Immersive Virtual Reality, No distraction Control condition; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions: AOC-1020, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Orange, California • Palo Alto, California • Denver, Colorado + 11 more

Conditions: Regional Anesthesia, Sciatic Nerve Block
Interventions: Suture-Method Technique, Through-the-Needle Technique; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Military Service Members at Elevated Suicide Risk
Interventions: Cognitive Bias Modification Intervention for Help-Seeking Stigma, Placebo Cognitive Bias Modification (CBM-Placebo), Self-Directed Psychoeducation; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Tallahassee, Florida • Portsmouth, Virginia

Conditions: Complicated Intra-Abdominal Infection
Interventions: Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 7 Days to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 6 more

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years and older
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: La Mesa, California • Oklahoma City, Oklahoma • Fort Worth, Texas

Conditions: Colorectal Cancer
Interventions: Multimedia Education, Print Media, Usual and customary waiting room process; Behavioral
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 50 Years to 80 Years
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Highland Park, Illinois • North Chicago, Illinois • Waukegan, Illinois

Search by objective public record fields.

A Study of V132 in Healthy Older Participants (V132-001)

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

Acetaminophen Before Vaccines for Infants Study (AVIS)

Restrained vs Gripping String Techniques in Patients Undergoing Cesarean Delivery

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.

Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

Impact of Counseling and Education on Opioid Consumption After ACL Reconstruction

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Ampicillin for DYT-1 Dystonia Motor Symptoms

The Effective of Immersive Virtual Reality Distraction on Memory: Study 1

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Comparing Through-the-Needle With Suture-Method Catheter Designs for Popliteal Nerve Blocks

Increasing Help-Seeking in Military Service Members

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Tools for Improving Colorectal Cancer Screening Rates: Multimedia Versus Print